MediPharm Labs Corp
LABS
Company Profile
Business description
MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.
Contact
151 John Street
BarrieONL4N 2L1
CANT: +1 705 719-7425
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
161
Stocks News & Analysis
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks
New data centre deal for ASX listed REIT
New parternship adds to a growing data centre pipeline in fiscal 2026.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.70 | 2.20 | -0.02% |
| CAC 40 | 8,195.21 | 45.71 | 0.56% |
| DAX 40 | 24,539.34 | 48.93 | 0.20% |
| Dow JONES (US) | 48,382.39 | 319.10 | 0.66% |
| FTSE 100 | 9,951.14 | 19.76 | 0.20% |
| HKSE | 26,343.67 | 5.20 | 0.02% |
| NASDAQ | 23,235.63 | 6.36 | -0.03% |
| Nikkei 225 | 51,832.80 | 1,493.32 | 2.97% |
| NZX 50 Index | 13,587.23 | 38.81 | 0.29% |
| S&P 500 | 6,858.47 | 12.97 | 0.19% |
| S&P/ASX 200 | 8,728.60 | 2.60 | 0.03% |
| SSE Composite Index | 4,023.42 | 54.58 | 1.38% |